AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00322478 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blood Glucose Notifications to Remote Caregivers
Description: When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
Study NCT00322478 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of Pattern Management
Description: The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
Study NCT04572100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS) or Radiotherapy
Description: Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.
Study NCT04572100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and Low-Dose Radiotherapy
Description: Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.
Study NCT04572100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and High-Dose Radiotherapy
Description: Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.
Study NCT04572100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: This drug will be combined with carboplatin during induction therapy for 9 weeks.
Study NCT04572100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: This drug will be combined with paclitaxel during induction therapy for 9 weeks.
Study NCT04637997 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: compression stockings class I
Description: Daily wearing of compression stockings class I for four weeks on the affected extremity.
Study NCT04637997 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: compression stockings class II
Description: Daily wearing of compression stockings class II for four weeks on the affected extremity.
Study NCT02699164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal stabilization exercise
Description: spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
Study NCT01693952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood draw
Study NCT00375661 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: interferon-alfa-2b and ribavirin
Description: Interferon, pnce per week plus daily ribavirin
Study NCT03271697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Membranaceus
Description: This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
Study NCT03271697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as a comparator comparing with AM group
Study NCT00125918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study NCT00125918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study NCT00125918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study NCT03434990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation/myofascial release
Description: The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.
Study NCT03434990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning
Study NCT00125918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study NCT02240459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning
Study NCT00125918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken by mouth once a day for 16 weeks
Study NCT00446043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide
Description: Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
Study NCT04155736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renew
Description: Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
Study NCT04155736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Renew
Description: Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HYDRAL Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYDRAL Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04005872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride
Description: Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
Study NCT04005872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
Study NCT01649219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01993199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep biopsy via ESD technique
Study NCT01502553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison Test to Yuyue Medical BP Meter, YYBP-212
Description: DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HYDRAL Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOTENE® Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOTENE® Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BIOTENE® Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT01391611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg; PO
Study NCT01586325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 30 mg
Description: JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
Study NCT01586325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 90 mg
Description: JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
Study NCT01586325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 200 mg
Description: JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
Study NCT01586325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo administered once daily as monotherapy for 5 days.
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT04289051 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse
Description: Application 4 times a day for two weeks
Study NCT02018939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic profiling
Description: Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
Study NCT01901341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945
Study NCT02423408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201
Description: TNX-201 capsule
Study NCT02423408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT00486044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg tablet each night for one month, then 80 mg for 8 months
Study NCT00486044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet each night for 9 months
Study NCT04989673 — intervention group
Intervention type: OTHER
Intervention: Biological sampling and collection (serum)
Description: Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
Study NCT04989673 — intervention group
Intervention type: OTHER
Intervention: Biological sampling and collection (placenta)
Description: Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
Study NCT04989673 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
Study NCT04989673 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
Study NCT02422654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion
Study NCT01183923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli Sprouts
Description: Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.
Study NCT01183923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfalfa Sprouts
Description: Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
Study NCT01901341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03666377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: 1 piece of sugarless gum to be chewed three times daily for 1 hour each.
Study NCT01851499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ultramicronized PEA (Normast)
Description: 600 mg
Study NCT01851499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ultramicronized PEA (Normast)
Description: 600 mg
Study NCT03848013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q switched Nd YAG laser
Description: Laser device emitting Q switched Nd YAG aiming for skin toning
Study NCT03848013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Laser device emitting fractionated ablative laser aiming for skin resurfacing
Study NCT00962403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga treatment
Description: The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
Study NCT04392661 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Description: bariatric surgeries and data collection
Study NCT01627548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Approach Therapy
Description: The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
Study NCT00630916 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Mitroflow Aortic Heart Valve
Description: Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
Study NCT01556217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Study NCT01556217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Study NCT04656990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention
Description: Gross motor and social-emotional integrated intervention
Study NCT03874611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological data from DBS
Description: For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
Study NCT00406055 — intervention group
Intervention type: DEVICE
Intervention: RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
Description: Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
Study NCT02389582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Use for 5 days
Study NCT02389582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Use for 5 days
Study NCT01658332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 3 tubes (15 ml)
Study NCT00942136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
Study NCT00942136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
Study NCT00942136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Suspension as a single dose.
Study NCT00942136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
Study NCT02456896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
Study NCT00627692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 0.5 mg o.d.
Study NCT00627692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study NCT00627692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg o.d.
Study NCT00627692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.